LRRK2 Antibody (YA4330)
(Synonyms: PARK8; RIPK7; ROCO2; AURA17; DARDARIN)LRRK2 Antibody (YA4330) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
IHC-P, FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
LRRK2 Antibody (YA4330) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 280 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 286 kDa
Purified recombinant fragment of human LRRK2 (AA: 300-530) expressed in E. Coli.
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Leucine-rich repeat kinase 2 (LRRK2) is a ubiquitously expressed member of the ROCO protein family. LRRK2 is a complex, multidomain protein containing kinase and GTPase enzymatic activities and multiple protein-protein interaction domains. LRRK2 is the genetic cause of both familial and idiopathic Parkinson's disease (PD), and it is associated with neuronal death, vesicle trafficking, mitochondrial dysfunction, and inflammation. LRRK2 is a very large protein comprised of 2527 amino acids which has been determined to contain multiple functional domains, including armadillo (ARM), ankyrin-repeats (ANK), leucine-rich repeats (LRR), Ras of complex proteins (ROC), C-terminal of Roc (COR), MAPK-like kinase, and WD40 motifs. Mutations in LRRK2 represent a significant component of both sporadic and familial PD. Pathogenic mutations cluster in the enzymatic domains of LRRK2, and kinase activity seems to correlate with cytotoxicity, suggesting the possibility of kinase-based therapeutic strategies for LRRK2-associated PD. The best-characterized mutation to date, G2019S, leads to increased kinase activity, and mutations in the GTPase domain, such as R1441C and R1441G, have also been reported to influence kinase activity.
-
Subcellular Localization
Cytoplasmic vesicle; Perikaryon; Golgi apparatus membrane; Peripheral membrane protein; Cell projection, axon; Cell projection, dendrite; Endoplasmic reticulum membrane; Peripheral membrane protein; Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane; Endosome; Lysosome; Mitochondrion outer membrane; Peripheral membrane protein; Cytoplasm, cytoskeleton; Cytoplasmic vesicle, phagosome
-
Expression
Tissue_specificity:It is expressed (protein level) in pyramidal neurons of all cortical layers of the visual cortex, neurons of the substantia nigra pars compacta, and neurons of the putamen of the caudate nucleus. It is also expressed (protein level) in neutrophils (PubMed:29127255) . It is also expressed in the brain. It is expressed throughout the adult brain, but at lower levels than in the heart and liver. It is also expressed in the placenta, lungs, skeletal muscle, kidneys, and pancreas. In the brain, it is expressed in the cerebellum, cerebral cortex, medulla oblongata, occipital pole of the spinal cord, frontal lobe, temporal lobe, and putamen. Expression is particularly strong in dopaminergic regions of the brain. -
Subunit
Homodimer (PubMed:18230735, PubMed:22952686, PubMed:30635421, PubMed:38127736). Homotetramer; when activated by GTP-bound RAB29 (PubMed:38127736). Interacts with PRKN, PRDX3, and TPCN2 (PubMed:16352719, PubMed:21850687, PubMed:22012985). Interacts with VPS35 (PubMed:23395371). Interacts (via N-terminus) with RAB29; this interaction is direct and stimulates kinase activity (PubMed:23395371, PubMed:38127736). Interacts (via ROC domain) with SEC16A (PubMed:25201882). Interacts with APP; interaction promotes phosphorylation of 'Thr-743' of APP (PubMed:28720718). Interacts with MAPT (PubMed:26014385). Interacts with RAB8A, RAB10, and RAB12 (PubMed:26824392). Interacts (via N-terminus) with RAB32 (PubMed:38127736). Interacts with YWHAG; this interaction is dependent on phosphorylation of Ser-910 and either Ser-935 or Ser-1444 (PubMed:28202711). Interacts with SFN; this interaction is dependent on phosphorylation of Ser-910 and/or Ser-935 (PubMed:28202711)
-
SwissProt ID
-
Synonyms
PARK8; RIPK7; ROCO2; AURA17; DARDARIN
Documentation
Powered by Bioz
